NASDAQ:AKRO Akero Therapeutics Q1 2025 Earnings Report ProfileEarnings HistoryForecast Akero Therapeutics EPS ResultsActual EPS$0.90Consensus EPS -$1.01Beat/MissBeat by +$1.91One Year Ago EPSN/AAkero Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkero Therapeutics Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Akero Therapeutics Earnings HeadlinesNovo Nordisk has completed its acquisition of Akero TherapeuticsDecember 9, 2025 | globenewswire.comAkero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRONovember 20, 2025 | businesswire.comYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI data centers are already obsolete. Three companies are quietly developing a way to process data that could do in minutes what current server farms do in hours, using up to 90% less energy. Gilder calls it the 'Trillion Dollar Triangle' - and he thinks it could reshape the AI landscape the same way digital streaming buried Blockbuster.May 24 at 1:00 AM | Eagle Publishing (Ad)Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)November 12, 2025 | prnewswire.comAkero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price GainsNovember 10, 2025 | finance.yahoo.comAkero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025November 7, 2025 | globenewswire.comSee More Akero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email. Email Address About Akero TherapeuticsAkero Therapeutics (NASDAQ:AKRO) is a clinical-stage biotechnology company focused on developing novel therapies for severe metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s research platform leverages engineered versions of endocrine hormones to target key pathways involved in lipid metabolism, glucose regulation and tissue fibrosis. By harnessing the biology of fibroblast growth factor 21 (FGF21), Akero aims to address underlying drivers of metabolic dysfunction rather than merely treating symptoms. The company’s lead product candidate, efruxifermin, is an Fc-FGF21 fusion protein designed to improve liver health and metabolic parameters in patients with NASH. Efruxifermin has demonstrated reductions in liver fat content, improvements in markers of liver injury and favorable changes in lipid and glucose profiles in early-phase clinical studies. Akero is advancing efruxifermin through pivotal trials, including global Phase 2 and Phase 3 studies, with the goal of achieving regulatory approval for patients with advanced liver fibrosis due to NASH. Founded in 2017 and headquartered in Boston, Massachusetts, Akero Therapeutics operates research and development facilities in North America while engaging clinical sites across the United States and Europe. The company’s scientific leadership comprises experts in metabolic disease biology, protein engineering and drug development, supported by advisory collaborations with leading academic institutions. Akero’s board includes seasoned biotech investors and executives who guide its strategic direction. In addition to its lead program, Akero is exploring preclinical candidates that modulate other hormone pathways implicated in cardiometabolic and fibrotic disorders. Through partnerships with contract research organizations and regulatory agencies, the company aims to expand its pipeline and ultimately deliver new treatment options for patients suffering from metabolic and liver diseases worldwide.View Akero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsOverextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
